References

Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric : the journal of the International Menopause Society. 2001 Dec;4(4):267–72. [PubMed: 11770182]

Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001. Menopause. 2001 Nov-Dec;8(6):402–7. [PubMed: 21141649]

Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001 Nov;76(5):874–8. [PubMed: 11704104]

Amundsen DW, Diers CJ. The age of menopause in classical Greece and Rome. Hum Biol. 1970 Feb;42(1):79–86. [PubMed: 4910710]

North American Menopause Society. Menopause Practice: A Clinician's Guide. 4th Edition ed. Mayfield Heights, OH: North American Menopause Society; 2010.

Harlow S. Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. J Clin Endocrinol Metab. 2012;97(4):1159–68. PMID: [PMC free article: PMC3319184] [PubMed: 22344196]

McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992 Jan;14(2):103–15. [PubMed: 1565019]

Nelson HD, Haney E, Humphrey L, et al. Management of menopause-related symptoms. Evid Rep Technol Assess (Summ). 2005 Mar;(120):1–6. [PMC free article: PMC4782129] [PubMed: 15910013]

Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med. 2005 Dec 19;118 Suppl 12B:14–24. [PubMed: 16414323]

Proceedings from the NIH State-of-the-Science Conference on Management of Menopause-Related Symptoms; Am J Med; March 21-23, 2005; Bethesda, Maryland, USA. Dec 19, 2005. pp. 1–171. [PubMed: 16414320]

Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med. 2008 Sep;23(9):1507–13. [PMC free article: PMC2518020] [PubMed: 18521690]

Freeman EW, Sammel MD, Lin H, et al. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol. 2011 May;117(5):1095–104. [PMC free article: PMC3085137] [PubMed: 21508748]

Gold EB, Block G, Crawford S, et al. Lifestyle and demographic factors in relation to vasomotor symptoms: baseline results from the Study of Women's Health Across the Nation. Am J Epidemiol. 2004 Jun 15;159(12):1189–99. [PubMed: 15191936]

Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999 Apr 6;130(7):545–53. [PubMed: 10189323]

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321–33. [PubMed: 12117397]

Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol. 2005 Sep 1;162(5):404–14. [PubMed: 16033876]

Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011 Apr;18(4):385–92. [PMC free article: PMC3123410] [PubMed: 21127439]

Somboonporn. Testosterone for peri and postmenopausal women. Cochrane Database Syst Rev. 2005(4) [PubMed: 16235365]

North American Menopause S. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012 Mar;19(3):257–71. [PMC free article: PMC3443956] [PubMed: 22367731]

Bioidentical hormones. Med Lett Drugs Ther. 2010 May 31;52(1339):43–4. [PubMed: 20508582]

Siyam T, Yuksel N. Abstract: Bioidentical Hormone Therapy: A Survey of Pharmacists Beliefs. Menopause. 2011;18(12):1. PMID:

Iftikhar S, Shuster L, Johnson R, et al. Abstract: Use of Bio-identical Hormones in Patients Presenting to a Women's Health Clinic. Menopause. 14(6):1. 207. PMID:

Galston SK. Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients. 2003. [cited 2014 October]; Available from: http://www​.fda.gov/NewsEvents​/Testimony/ucm115010.htm.

Patsner B. What every scientist should know about FDA. 2004. [cited 2014 October 13]; Available from: https:​//baylorcollegeofmedicine​.org/pda/index.cfm?pmid=9920.

Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006 May 3;295(17):2057–71. [PubMed: 16670414]

Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002 Mar 15;20(6):1578–83. [PubMed: 11896107]

Bair YA, Gold EB, Zhang G, et al. Use of complementary and alternative medicine during the menopause transition: longitudinal results from the Study of Women's Health Across the Nation. Menopause. 2008 Jan-Feb;15(1):32–43. [PubMed: 18090037]

Nelson HD, Walker M, Zakher B, et al. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 US Preventive Services Task Force Recommendations. Rockville (MD): 2012. [PubMed: 22720332]

Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010 Mar;17(2):242–55. [PubMed: 20154637]

Pines A, Sturdee DW, Birkhauser MH, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007 Jun;10(3):181–94. [PubMed: 17487645]

Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1–s66. [PMC free article: PMC6287288] [PubMed: 20566620]

The American College of Obstetricians and Gynecologists Committee Opinion: Compounded Bioidentical Hormones. Obstetrics & Gynecology. 2005;106(5):2. PMID:

U.S. FDA. Compounded Menopausal Hormone Therapy Questions and Answers. US Food and Drug Administration. 2010. [cited 2014 October]; Available from: http://www​.fda.gov/Drugs​/GuidanceComplianceRegulatoryInformation​/PharmacyCompounding/ucm183088.htm.

Szmuilowicz ED, Manson JE, Rossouw JE, et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause. 2011 Jun;18(6):603–10. [PMC free article: PMC3123435] [PubMed: 21358352]

Welton AJ, Vickers MR, Kim J, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ. 2008;337:a1190. [PMC free article: PMC2518695] [PubMed: 18719013]

Loprinzi CL, Diekmann B, Novotny PJ, et al. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. Menopause. 2009 Sep-Oct;16(5):883–7. [PubMed: 19295449]

AHRQ. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2014.

The Endocrine Society Position Statement: Bioidentical Hormones. 2006. [cited 2014 October]; Position Statement]. Available from: https://www​.endocrine​.org/~/media/endosociety​/Files/Advocacy%20and%20Outreach​/Position%20Statements​/All​/BH_Position_Statement​_final_10_25_06_w_Header.pdf.

American Association of Clinical Endocrinologists (AACE) Reproductive Medicine Committee Position Statement on Bioidentical Hormones. 2007. [cited 2014 October]; Available from: https://www​.aace.com​/files/position-statements​/aacebhstatement071507.pdf.

SPECIAL COMMITTEE ON AGING UNITED STATES SENATE. Bioidentical Hormones: Sound Science or Bad Medicine. 2007. [cited 2014 October]; Available from: www​.aging.senate.gov​/download/hearing-041907.

Somers S. Ageless: The Naked Truth About Bioidentical Hormones. 1st ed. New York: Crown Publishers; 2006.

Guttuso T Jr, Kurlan R, et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003 Feb;(2):337–45. [PubMed: 12576259]

Prentice RL. Observational studies, clinical trials, and the women's health initiative. Lifetime data analysis. 2007 Dec;13(4):449–62. [PubMed: 17943443]

Tanaka S, Matsuyama Y, Shiraki M, et al. Estimating the effects of time-varying treatments: incidence of fractures among postmenopausal Japanese women. Epidemiology. 2007 Sep;18(5):529–36. [PubMed: 17700241]

Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008 Nov;19(6):766–79. [PMC free article: PMC3731075] [PubMed: 18854702]

Morois S, Fournier A, Clavel-Chapelon F, et al. Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias? Eur J Epidemiol. 2012 Jun;27(6):439–52. [PubMed: 22644109]

Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009 Jul 1;170(1):12–23. [PMC free article: PMC2733042] [PubMed: 19468079]

Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2009(2):CD000402. [PubMed: 19370558]

R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. Available from: http://www​.R-project.org/

Organization MMaSS. Introductory Guide to MeDRA Version 14.0. Chantilly, VA: International Federation of Pharmaceutical Manufacturers and Associations; 2011.

Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. American journal of preventive medicine. 2001 Apr;20(3 Suppl):21–35. [PubMed: 11306229]

Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. [PMC free article: PMC1810543] [PubMed: 17302989]

Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. 2012. In: Quality AfHRa, editor.

Hernán MA, Robins JM. Estimating causal effects from epidemiological data. Journal of epidemiology and community health. 2006 Jul;60(7):578–86. [PMC free article: PMC2652882] [PubMed: 16790829]

Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2006 Feb 28;174(5):645–6. [PMC free article: PMC1389828] [PubMed: 16505461]

Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of clinical epidemiology. 2011 Apr;64(4):401–6. [PubMed: 21208779]

Gøtzsche PC, Hrobjartsson A, Maric K, et al. Data extraction errors in meta-analyses that use standardized mean differences. JAMA. 2007 Jul 25;298(4):430–7. [PubMed: 17652297]

Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of clinical epidemiology. 2011 Nov;64(11):1187–97. [PubMed: 21477993]

Schwarzer G. meta: Meta-Analysis with R (version 3.6-0). 2014. [cited 2014 July 31]; Available from: http://CRAN​.R-project.org/package=meta.

Re ACD. compute.es: Compute Effect Sizes. 2013. [cited 2014 July 31]; Available from: http://CRAN​.R-project​.org/web/packages/compute.es.

Wickham H. ggplot2: elegant graphics for data analysis. Springer; New York: 2009.

Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis. Psychol Meth. 1998;3(4):486–504. PMID: none.

Rucker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8:79. [PMC free article: PMC2648991] [PubMed: 19036172]

Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause. 2003 Sep-Oct;10(5):465–76. [PubMed: 14501609]

Kupperman HS, Wetchler BB, Blatt MH. Contemporary therapy of the menopausal syndrome. Journal of the American Medical Association. 1959 Nov 21;171:1627–37. [PubMed: 14412840]

Morrison MF, Kallan MJ, Ten Have T, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biological psychiatry. 2004 Feb 15;55(4):406–12. [PubMed: 14960294]

Zollner YF, Acquadro C, Schaefer M. Literature review of instruments to assess health-related quality of life during and after menopause. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2005 Mar;14(2):309–27. [PubMed: 15892422]

Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 2008 Sep-Oct;61(1-2):107–21. [PubMed: 19434884]

Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas. 2005 Mar 14;50(3):209–21. [PubMed: 15734602]

Wyrwich KW, Fihn SD, Tierney WM, et al. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med. 2003 Mar;18(3):196–202. [PMC free article: PMC1494834] [PubMed: 12648251]

Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics. 1999 Feb;15(2):141–55. [PubMed: 10351188]

Levine DW, Dailey ME, Rockhill B, et al. Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial. Psychosomatic medicine. 2005 Jan-Feb;67(1):98–104. [PubMed: 15673630]

DeRogatis LR, Graziottin A, Bitzer J, et al. Clinically relevant changes in sexual desire, satisfying sexual activity and personal distress as measured by the profile of female sexual function, sexual activity log, and personal distress scale in postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2009 Jan;6(1):175–83. [PubMed: 19170847]

Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003 Mar 1;326(7387):472. [PMC free article: PMC150178] [PubMed: 12609941]

Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. Journal of clinical epidemiology. 2010 May;63(5):513–23. [PubMed: 19595577]

Treadwell JR, Uhl S, Tipton K, et al. Assessing equivalence and noninferiority. Journal of clinical epidemiology. 2012 Nov;65(11):1144–9. [PubMed: 22732455]

Fu R, Vandermeer BW, Shamliyan TA, et al. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): 2013. Handling Continuous Outcomes in Quantitative Synthesis.

Moher D, Liberati A, Tetzlaff J, et al. Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009 Sep;89(9):873–80. [PubMed: 19723669]

Johnston BC, Patrick DL, Thorlund K, et al. Patient-reported outcomes in meta-analyses-part 2: methods for improving interpretability for decision-makers. Health Qual Life Outcomes. 2013;11:211. [PMC free article: PMC3984637] [PubMed: 24359184]

Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. Journal of clinical epidemiology. 2013 Feb;66(2):173–83. [PubMed: 23116689]

Sloan JA, Loprinzi CL, Novotny PJ, et al. Methodologic lessons learned from hot flash studies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Dec 1;19(23):4280–90. [PubMed: 11731510]

Carroll DG, Kelley KW. Use of antidepressants for management of hot flashes. Pharmacotherapy. 2009 Nov;29(11):1357–74. [PubMed: 19857151]

Wyrwich KW, Spratt DI, Gass M, et al. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause. 2008 Jul-Aug;15(4 Pt 1):698–705. [PubMed: 18369313]

Oktem M, Eroglu D, Karahan HB, et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther. 2007 Mar-Apr;(2):448–61. [PubMed: 17565936]

Kaari C, Haidar MA, Junior JM, et al. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. Maturitas. 2006 Jan;10(1):49–58. [PubMed: 16257151]

Schellenberg R, Saller R, Hess L, et al. Dose-Dependent Effects of the Cimicifuga racemosa Extract Ze 450 in the Treatment of Climacteric Complaints: A Randomized, Placebo-Controlled Study. Evidence-based complementary and alternative medicine : eCAM. 2012;2012:260301. [PMC free article: PMC3544165] [PubMed: 23346194]

Hidalgo LA, Chedraui PA, Morocho N, et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol Endocrinol. 2005 Nov;(5):257–64. [PubMed: 16373244]

Wiklund IK, Mattsson LA, Lindgren R, et al. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int J Clin Pharmacol Res. 1999(3):89–99. [PubMed: 10761538]

Hartley DE, Elsabagh S, File SE. Gincosan (a combination of Ginkgo biloba and Panax ginseng): the effects on mood and cognition of 6 and 12 weeks' treatment in post-menopausal women. Nutr Neurosci. 2004 Oct-Dec;(5-6):325–33. [PubMed: 15682929]

Odabasi AR, Yuksel H, Demircan SS, et al. A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology. J Postgrad Med. 2007 Oct-Dec;(4):221–7. [PubMed: 18097108]

Davis SR, Davison SL, Wilson S, et al. Intranasal versus transdermal matrix oestrogen replacement in Australasian women. Maturitas. 2005 Jun;16(2):163–71. [PubMed: 15917157]

Ozsoy M, Oral B, Ozsoy D. Clinical equivalence of intranasal estradiol and oral estrogens for postmenopausal symptoms. Int J Gynaecol Obstet. 2002 Nov;(2):143–6. [PubMed: 12427399]

Lopes P, Rozenberg S, Graaf J, et al. Aerodiol versus the transdermal route: perspectives for patient preference. Maturitas. 2001 Jun;15:S31–9. [PubMed: 11390122]

Mattsson LA, Christiansen C, Colau JC, et al. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol. 2000 Mar;(3):545–52. [PubMed: 10739506]

Studd JW, McCarthy K, Zamblera D, et al. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas. 1995 Sep;(2):105–14. [PubMed: 8538478]

Parsey K, Ellman H, Rahman M. Randomised, controlled comparison of transdermal estradiol with oral conjugated estrogens for the relief of hot flushes. Clinical Drug Investigation. 2000;(4):207–14. PMID:

Good WR, John VA, Ramirez M, et al. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group. Climacteric. 1999 Mar;(1):29–36. [PubMed: 11915854]

Serrano D, Mariani L, Mora S, et al. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT. Maturitas. 2006 Aug;20(1):69–75. [PubMed: 16500052]

Akhila V, Pratapkumar A comparison of transdermal and oral HRT for menopausal symptom control. Int J Fertil Womens Med. 2006 Mar-Apr;(2):64–9. [PubMed: 16881381]

Rozenberg S, Ylikorkala O, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fertil Womens Med. 1997:376–87. [PubMed: 9397385]

Gambacciani M, Spielmann D, Genazzani AR. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate. Gynecol Endocrinol. 2005 Aug;(2):65–73. [PubMed: 16294457]

Benster B, Carey A, Wadsworth F, et al. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int. 2009 Jun;15(2):63–9. [PubMed: 19465671]

Wren BG, Champion SM, Willetts K, et al. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause. 2003 Jan-Feb;(1):13–8. [PubMed: 12544672]

Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol. 1999 Aug;(2):225–8. [PubMed: 10432132]

Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. American Journal of Obstetrics & Gynecology. 2010;202(2):11. [PubMed: 20035910]

Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. British medical journal. 1974 Mar 9;1(5905):409–12. [PMC free article: PMC1633257] [PubMed: 4593554]

Haines CJ, Lam PM, Chung TK, et al. A randomized, double-blind, placebo-controlled study of the effect of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) on menopausal symptoms in Hong Kong Chinese women. Climacteric. 2008 Jun;11(3):244–51. [PubMed: 18568789]

Garcia JT, Gonzaga F, Tan D, et al. Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study. Menopause. 2010 Mar;(2):303–8. [PubMed: 19934777]

van der Sluijs CP, Bensoussan A, Chang S, et al. A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms. Menopause. 2009 Mar-Apr;(2):336–44. [PubMed: 19057416]

Yang HM, Liao MF, Zhu SY, et al. A randomised, double-blind, placebo-controlled trial on the effect of Pycnogenol on the climacteric syndrome in peri-menopausal women. Acta Obstet Gynecol Scand. 2007(8):978–85. [PubMed: 17653885]

Mucci M, Carraro C, Mancino P, et al. Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause. Minerva Ginecol. 2006 Aug;(4):323–34. [PubMed: 16957676]

Heger M, Ventskovskiy BM, Borzenko I, et al. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. Menopause. 2006 Sep-Oct;(5):744–59. [PubMed: 16894335]

Winther K, Rein E, Hedman C. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric. 2005 Jun;(2):162–70. [PubMed: 16096172]

Davis SR, Briganti EM, Chen RQ, et al. The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. A randomised controlled trial. Med J Aust. 2001 Jan;15(2):68–71. [PubMed: 11245505]

Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997 Dec;(6):981–6. [PubMed: 9418683]

Chenoy R, Hussain S, Tayob Y, et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ. 1994 Feb;19(6927):501–3. [PMC free article: PMC2542782] [PubMed: 8136666]

Hsu CC, Kuo HC, Chang SY, et al. The assessment of efficacy of Diascorea alata for menopausal symptom treatment in Taiwanese women. Climacteric. 2011 Feb;(1):132–9. [PubMed: 20653397]

Auerbach L, Rakus J, Bauer C, et al. Pomegranate seed oil in women with menopausal symptoms: a prospective randomized, placebo-controlled, double-blinded trial. Menopause. 2012 Jan 11 [PubMed: 22240636]

Chang A, Kwak BY, Yi K, et al. The Effect of Herbal Extract (EstroG-100) on Pre-, Peri- and Post-Menopausal Women: A Randomized Double-blind, Placebo-controlled Study. Phytother Res. 2011 Sep 2 [PubMed: 21887807]

Xia Y, Zhao Y, Ren M, et al. A randomized double-blind placebo-controlled trial of a Chinese herbal medicine preparation (Jiawei Qing'e Fang) for hot flashes and quality of life in perimenopausal women. Menopause. 2012(2):234–44. [PubMed: 22089177]

von Hagens C, Schiller P, Godbillon B, et al. Treating menopausal symptoms with a complex remedy or placebo: a randomized controlled trial. Climacteric. 2012 Aug;15(4):358–67. [PubMed: 22017387]

Yang H, Yang J, Wen Z, et al. Effect of combining therapy with traditional chinese medicine-based psychotherapy and herbal medicines in women with menopausal syndrome: a randomized controlled clinical trial. Evidence-based complementary and alternative medicine : eCAM. 2012;2012:354145. [PMC free article: PMC3523610] [PubMed: 23304198]

Zhong LL, Tong Y, Tang GW, et al. A randomized, double-blind, controlled trial of a Chinese herbal formula (Er-Xian decoction) for menopausal symptoms in Hong Kong perimenopausal women. Menopause. 2013 Jul;20(7):767–76. [PubMed: 23793167]

Plotnikoff GA, Watanabe K, Torkelson C, et al. The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women: Results and lessons for future research. Menopause. 2011(8):886–92. [PMC free article: PMC3181094] [PubMed: 21738077]

Kohama T, Negami M. Effect of low-dose French maritime pine bark extract on climacteric syndrome in 170 perimenopausal women: a randomized, double-blind, placebo-controlled trial. The Journal of reproductive medicine. 2013 Jan-Feb;58(1-2):39–46. [PubMed: 23447917]

Chung DJ, Kim HY, Park KH, et al. Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms. Yonsei Med J. 2007 Apr;30(2):289–94. [PMC free article: PMC2628120] [PubMed: 17461529]

Verhoeven MO, Mooren MJvd, Weijer PHvd, et al. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause. 2005 Jul-Aug;(4):412–20. [PubMed: 16037756]

Uebelhack R, Blohmer JU, Graubaum HJ, et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol. 2006 Feb;(2 Pt 1):247–55. [PubMed: 16449108]

Die MDv, Burger HG, Bone KM, et al. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause. 2009 Jan-Feb;(1):156–63. [PubMed: 18791483]

Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab. 1999 Nov;(11):3896–902. [PubMed: 10566625]

Dodin S, Lemay A, Jacques H, et al. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005 Mar;(3):1390–7. [PubMed: 15613422]

Andrikoula M, Baker D, Nesic J, et al. The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women. Climacteric. 2011(5):544–50. [PubMed: 21413865]

Pandit S, Umbardand S, Ghodake V, et al. Evaluation of the efficacy and tolerability of micronutrient supplementation in treatment of post menopausal symptoms. Internet Journal of Genomics and Proteomics. 2012;6(2) PMID:

Chandeying V, Sangthawan M. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study. J Med Assoc Thai. 2007 Sep;(9):1720–6. [PubMed: 17957910]

Menati L, Khaleghinezhad K, Tadayon M, et al. Evaluation of contextual and demographic factors on licorice effects on reducing hot flashes in postmenopause women. Health care for women international. 2014 Jan;35(1):87–99. [PubMed: 23663094]

Virojchaiwong P, Suvithayasiri V, Itharat A. Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms. Archives of Gynecology and Obstetrics. 2011(2):411–9. [PubMed: 20872225]

Yang TS, Wang SY, Yang YC, et al. Effects of standardized phytoestrogen on Taiwanese menopausal women. Taiwanese journal of obstetrics & gynecology. 2012 Jun;51(2):229–35. [PubMed: 22795099]

Agosta C, Atlante M, Benvenuti C. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause. Minerva Ginecol. 2011 Feb;63(1):11–7. [PubMed: 21311416]

Zervoudis SI, G., Navrozoglou I, Tsionis C, Chaniotis D, Diakakis I. Soja Isoflavones with Lactobascillus Sporogenes in Recent Menopause Women: Effects on Clinical Symptoms and Bone Density: A Comparative Prospective Study of 62 Patients; 12th World Congress on Menopause; Climacteric; Madrid, Spain. Climacteric; 2008. p. 223. (Abstract PS-32)

Raynaud JP, Levrier M, Calaf J, et al. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system. J Steroid Biochem Mol Biol. 2005 Feb;(2-5):309–18. [PubMed: 15860275]

Hidalgo MJC, Castelo-Branco C, Blumel JE, et al. Effect of a compound containing isoflavones, primrose oil and vitamin E in two different doses on climacteric symptoms. J Obstet Gynaecol. 2006 May;(4):344–7. [PubMed: 16753687]

Lobo RA, Rosen RC, Yang HM, et al. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril. 2003 Jun;(6):1341–52. [PubMed: 12798881]

Gupta B, Mittal P, Khuteta R, et al. A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India. 2013;63(3):194–8. PMID: [PMC free article: PMC3696143] [PubMed: 24431637]

Brunner RL, Gass M, Aragaki A, et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med. 2005 Sep;26(17):1976–86. [PubMed: 16186467]

Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003 May;8(19):1839–54. [PubMed: 12642637]

Lubbert H, Nauert C. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. Maturitas. 1997 Dec;15(2):117–25. [PubMed: 9522319]

Polvani F, Zichella L, Bocci A, et al. A randomized comparative study for the clinical evaluation of hormone replacement by transdermal and oral routes. Clin Exp Obstet Gynecol. 1991(4):207–13. [PubMed: 1790601]

Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001 Jun;(6):529–34. [PubMed: 11386980]

Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009 Sep-Oct;(5):923–31. [PubMed: 19424093]

Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med. 2009 Sep;(9):2579–90. [PubMed: 19619146]

Sammartino A, Tommaselli GA, Gargano V, et al. Short-term effects of a combination of isoflavones, lignans and Cimicifuga racemosa on climacteric-related symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled trial. Gynecol Endocrinol. 2006 Nov;(11):646–50. [PubMed: 17145651]

Lewis JE, Nickell LA, Thompson LU, et al. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause. 2006 Jul-Aug;(4):631–42. [PubMed: 16837885]

Shen CL, Chyu MC, Pence BC, et al. Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report. BMC Complement Altern Med. 2010:76. [PMC free article: PMC3014873] [PubMed: 21143878]

Veerus P, Fischer K, Hovi SL, et al. Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Womens Health. 2008;5 [PMC free article: PMC2330032] [PubMed: 18366766]

Liske E, Hanggi W, Zepelin HHH-v, et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med. 2002 Mar;(2):163–74. [PubMed: 11975864]

Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas. 1991 Jun;(2):99–107. [PubMed: 1921739]

Greene JG. Constructing a standard climacteric scale. Maturitas. 1998 May 20;29(1):25–31. [PubMed: 9643514]

Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988 Dec;56(6):893–7. [PubMed: 3204199]

Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4(6):561–71. [PubMed: 13688369]

Hamilton M. The assessment of anxiety states by rating. The British journal of medical psychology. 1959;32(1):50–5. [PubMed: 13638508]

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56–62. [PMC free article: PMC495331] [PubMed: 14399272]

Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001 Jul;33(5):350–7. [PubMed: 11491194]

Kupperman HS. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab. 1953;13:688–703. [PubMed: 13061588]

Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005 Jan;(1):161–6. [PubMed: 15625158]

Kalay A, Demir B, Haberal A, et al. Efficacy of citalopram on climacteric symptoms. Menopause: The Journal of The North American Menopause Society. 2007;14(2):7. [PubMed: 17224858]

Bouchard P, Panay N, Villiers TJD, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012(1):12–20. [PubMed: 22066790]

Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011 Jan 19;305(3):267–74. [PMC free article: PMC3129746] [PubMed: 21245182]

Pinkerton JV, Archer DF, Guico-Pabia CJ, et al. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause. 2013 Jan;20(1):38–46. [PubMed: 23266839]

Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005 Jan-Feb;(1):18–26. [PubMed: 15668596]

Soares CN, Joffe H, Viguera A, et al. Paroxetine Versus Placebo for Women in Midlife After Hormone Therapy Discontinuation. The American Journal of Medicine. 2008;121(2):5. [PubMed: 18261506]

Archer DF, Dupont CM, Constantine GD, et al. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol. 2009 Mar;(3):238 e1-e10. [PubMed: 19167693]

Kornstein SG, Jiang Q, Reddy S, et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. The Journal of clinical psychiatry. 2010 Aug;71(8):1088–96. [PubMed: 20797382]

Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol. 1993 Mar;(3 Pt 1):824–30. [PubMed: 8456888]

Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy -- a placebo-controlled study. Int J Fertil Menopausal Stud. 1995 Mar-Apr;(2):73–8. [PubMed: 7599662]

Baerug U, Winge T, Nordland G, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric. 1998 Sep;(3):219–28. [PubMed: 11907946]

Rozenbaum H, Chevallier O, Moyal M, et al. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. Climacteric. 2002 Sep;(3):249–58. [PubMed: 12419083]

Gelfand MM, Moreau M, Ayotte NJ, et al. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause. 2003 Jan-Feb;10(1):29–36. [PubMed: 12544674]

Haines CJ, Yim SF, Chung TK, et al. A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas. 2003 Mar;28(3):207–14. [PubMed: 12648884]

Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol. 2003 Oct;102(4):823–34. [PubMed: 14551014]

Yang TS, Wang HL, Chen YJ, et al. Effect of continuous administration of conjugated estrogen plus medroxyprogesterone acetate (Premelle) in postmenopausal women in Taiwan. J Chin Med Assoc. 2004 Jul;(7):336–43. [PubMed: 15510930]

Nielsen TF, Ravn P, Pitkin J, et al. Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study. Maturitas. 2006 Jan;20(2):184–90. [PubMed: 16368471]

Simon JA, Bouchard C, Waldbaum A, et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007 Mar;(3):588–96. [PubMed: 17329509]

Utian W, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas. 2009 Aug 20;63(4):329–35. [PubMed: 19647382]

Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010 Apr;13(2):132–40. [PubMed: 19863455]

Demetrio FN, Renno J Jr, Gianfaldoni A, et al. Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women: a randomized double-blind, controlled study. Arch Womens Ment Health. 2011 Dec;14(6):479–86. [PubMed: 22016254]

Pinkerton JV, Pan K, Abraham L, et al. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. Menopause. 2013 Aug 12 [PubMed: 23942245]

Campbell S, Whitehead, et al. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol. 1977 Apr;(1):31–47. [PubMed: 322905]

Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract. 1981 Mar;(224):134–40. [PMC free article: PMC1971963] [PubMed: 6268783]

Saletu B, Brandstatter N, Metka M, et al. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology (Berl). 1995 Dec;(4):321–9. [PubMed: 8657828]

Bech P, Munk-Jensen N, Obel EB, et al. Combined versus sequential hormonal replacement therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures. Psychother Psychosom. 1998 Jul-Oct;(4-5):259–65. [PubMed: 9693354]

Polo-Kantola P, Erkkola R, Irjala K, et al. Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. Fertil Steril. 1999 May;(5):873–80. [PubMed: 10231049]

Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas. 2003 Feb;25(2):157–63. [PubMed: 12590012]

Rudolph I, Palombo-Kinne E, Kirsch B, et al. Influence of a continuous combined HRT (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression. Climacteric. 2004 Sep;(3):301–11. [PubMed: 15669555]

Onalan G, Onalan R, Selam B, et al. Mood scores in relation to hormone replacement therapies during menopause: a prospective randomized trial. Tohoku J Exp Med. 2005 Nov;(3):223–31. [PubMed: 16210834]

Pefanco MA, Kenny AM, Kaplan RF, et al. The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. J Am Geriatr Soc. 2007 Mar;(3):426–31. [PubMed: 17341247]

Baksu B, Baksu A, Goker N, et al. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial. Maturitas. 2009 Feb;20(2):140–5. [PubMed: 19179026]

Hassa H, Tanir HM, Oge T. Is placebo as effective as estrogen regimens on vasomotor symptoms in women with surgical menopause? Clin Exp Obstet Gynecol. 2010(2):135–7. [PubMed: 21077506]

Polisseni AF, Andrade AT, Ribeiro LC, et al. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study. Maturitas. 2013 Feb;74(2):172–8. [PubMed: 23201326]

Strickler R, Stovall DW, Merritt D, et al. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol. 2000 Sep;(3):359–65. [PubMed: 10960626]

Butt D, Deng L, Lewis J, et al. Minimal decrease in hot flashes desired by postmenopausal women in family practice. Menopause: The Journal of The North American Menopause Society. 2007;14(2):5. [PubMed: 17099324]

Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA. 2003 Jul;9(2):207–14. [PubMed: 12851275]

Kok L, Kreijkamp-Kaspers S, Grobbee DE, et al. A randomized, placebo-controlled trial on the effects of soy protein containing isoflavones on quality of life in postmenopausal women. Menopause. 2005 Jan-Feb;(1):56–62. [PubMed: 15668601]

Ho SC, Chan AS, Ho YP, et al. Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial. Menopause. 2007 May-Jun;(3 Pt 1):489–99. [PubMed: 17308499]

Basaria S, Wisniewski A, Dupree K, et al. Effect of high-dose isoflavones on cognition, quality of life, androgens, and lipoprotein in post-menopausal women. J Endocrinol Invest. 2009 Feb;(2):150–5. [PubMed: 19411814]

Evans M, Elliott JG, Sharma P, et al. The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas. 2011 Feb;(2):189–96. [PubMed: 21163595]

Amato P, Young RL, Steinberg FM, et al. Effect of soy isoflavone supplementation on menopausal quality of life. Menopause. 2013 Apr;20(4):443–7. [PubMed: 23211877]

Kotsopoulos D, Dalais FS, Liang YL, et al. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric. 2000 Sep;(3):161–7. [PubMed: 11910617]

Sousa-Munoz RLd, Filizola RG. Efficacy of soy isoflavones for depressive symptoms of the climacteric syndrome. Maturitas. 2009 May;20(1):89–93. [PubMed: 19339127]

Lipovac M, Chedraui P, Gruenhut C, et al. Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts. Maturitas. 2010 Mar;(3):258–61. [PubMed: 19948385]

Jassi HK, Jain A, Arora S, et al. Effect of soy proteins Vs soy isoflavones on lipid profile in postmenopausal women. Indian Journal of Clinical Biochemistry. 2010(2):201–7. [PMC free article: PMC3453111] [PubMed: 23105910]

Chi XX, Zhang T. The effects of soy isoflavone on bone density in north region of climacteric Chinese women. J Clin Biochem Nutr. 2013 Sep;53(2):102–7. [PMC free article: PMC3774930] [PubMed: 24062607]

Casini ML, Marelli G, Papaleo E, et al. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. Fertil Steril. 2006 Apr;(4):972–8. [PubMed: 16580383]

Nathorst-Boos J, Floter A, Jarkander-Rolff M, et al. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido--effects on sexuality and psychological general well-being. Maturitas. 2006 Jan;10(1):11–8. [PubMed: 16183220]

Zheng TP, Sun AJ, Xue W, et al. Efficacy and safety of Cimicifuga foetida extract on menopausal syndrome in Chinese women. Chinese medical journal. 2013;126(11):2034–8. [PubMed: 23769553]

Nappi RE, Malavasi B, Brundu B, et al. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol. 2005 Jan;(1):30–5. [PubMed: 15969244]

Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005 May;(5 Pt 1):1074–83. [PubMed: 15863547]

Soares CN. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause. 2010;17(4):700–11. [PubMed: 20539246]

Raz. Effects of menopausal hormone therapy on serum serotinin and self-report depression in healthy, recently menopausal women. J of Women's Health. 2013;22(3):18. PMID:

Yalamanchili V, Gallagher JC. Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause. 2012 Jun;19(6):697–703. [PMC free article: PMC3319337] [PubMed: 22205149]

Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause. 2009 Jul-Aug;(4):719–27. [PubMed: 19436223]

Freedman M, Kaunitz AM, Reape KZ, et al. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause. 2009 Jul-Aug;(4):735–41. [PubMed: 19252451]

Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause. 2004 Jan-Feb;(1):49–56. [PubMed: 14716182]

Simunic V, Banovic I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003 Aug;(2):187–97. [PubMed: 12873780]

Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct. 1999(3):171–6. [PubMed: 10430010]

Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 1992 Apr;21(2):137–44. [PubMed: 1587379]

Parsons A, Merritt D, Rosen A, et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol. 2003 Feb;(2):346–52. [PubMed: 12576260]

Cano A, Estevez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause. 2012 Oct;19(10):1130–9. [PubMed: 22914208]

Vestergaard P, Hermann AP, Stilgren L, et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure-a randomised controlled study. Maturitas. 2003 Oct;20(2):123–32. [PubMed: 14559383]

Simon JA, Reape KZ, Wininger S, et al. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil Steril. 2008 Oct;90(4):1132–8. [PubMed: 18053998]

Gast MJ, Freedman MA, Vieweg AJ, et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause. 2009 Mar-Apr;(2):247–56. [PubMed: 19034054]

Haines C, Yu SL, Hiemeyer F, et al. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial. Climacteric. 2009 Oct;(5):419–26. [PubMed: 19479489]

Raghunandan C, Agrawal S, Dubey P, et al. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med. 2010 Mar;(3):1284–90. [PubMed: 20102444]

Osmanagaoglu MA, Atasaral T, Baltaci D, et al. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women. Climacteric. 2006 Dec;(6):464–72. [PubMed: 17085380]

Maki PM, Gast MJ, Vieweg AJ, et al. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology. 2007 Sep;25(13):1322–30. [PubMed: 17893293]

Archer DF, Seidman L, Constantine GD, et al. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2009 Feb;(2):172 e1-10. [PubMed: 19110224]

Cianci A, Cicero AF, Colacurci N, et al. Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women. Gynecol Endocrinol. 2012 Feb 8 [PubMed: 22313171]

Colacurci N, De Franciscis P, Atlante M, et al. Endometrial, breast and liver safety of soy isoflavones plus Lactobacillus sporogenes in post-menopausal women. Gynecol Endocrinol. 2013 Mar;29(3):209–12. [PubMed: 23194023]

Davis SR, Mooren MJvd, Lunsen RHv, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause. 2006 May-Jun;(3):387–96. [PubMed: 16735935]

Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med. 2005 Jul;25(14):1582–9. [PubMed: 16043675]

Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005 Sep;(9):5226–33. [PubMed: 16014407]

Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005 May;(5 Pt 1):944–52. [PubMed: 15863529]

Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010 Apr;(2):121–31. [PubMed: 20166859]

Penteado SR, Fonseca AM, Bagnoli VR, et al. Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. Climacteric. 2008 Feb;(1):17–25. [PubMed: 18202961]

Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008 Nov;6(19):2005–17. [PubMed: 18987368]

Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause. 2006 Sep-Oct;(5):770–9. [PubMed: 16932240]

Cieraad D, Conradt C, Jesinger D, et al. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. Arch Gynecol Obstet. 2006 May;(2):74–80. [PubMed: 16491367]

Utian WH, Speroff L, Ellman H, et al. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. Menopause. 2005 Nov-Dec;(6):708–15. [PubMed: 16278614]

Loh FH, Chen LH, Yu SL, et al. The efficacy of two dosages of a continuous combined hormone replacement regimen. Maturitas. 2002 Feb;26(2):123–31. [PubMed: 11836043]

Limpaphayom KK, Darmasetiawan MS, Hussain RI, et al. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Climacteric. 2006 Jun;(3):204–14. [PubMed: 16766434]

Pitkin J, Smetnik VP, Vadasz P, et al. Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women. Menopause Int. 2007 Sep;(3):116–23. [PubMed: 17785037]

Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol. 1997 Jan;71(1):73–80. [PubMed: 9031963]

Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol. 1996 Apr;(4):351–8. [PubMed: 8605133]

Hilditch JR, Lewis J, Ross AH, et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas. 1996 Jul;(3):177–84. [PubMed: 8844631]

Buckler H, Al-Azzawi F. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. BJOG. 2003 Aug;(8):753–9. [PubMed: 12892687]

Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005 Mar;(1):83–92. [PubMed: 15804736]

Long CY, Liu CM, Hsu SC, et al. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause. 2006 Sep-Oct;(5):737–43. [PubMed: 16946685]

Henriksson L, Stjernquist M, Boquist L, et al. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol. 1994 Sep;(3):624–32. [PubMed: 8092207]

Constantine G, Graham S, Koltun WD, et al. Assessment of Ospemifene or Lubricants on Clinical Signs of VVA. J Sex Med. 2014 Jan 21 [PubMed: 24443923]

Lima SM, Yamada SS, Reis BF, et al. Effective treatment of vaginal atrophy with isoflavone vaginal gel. Maturitas. 2013 Jan 8 [PubMed: 23312487]

Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008 Jan;(1):67–76. [PubMed: 18165394]

Chung TK, Yip SK, Lam P, et al. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms. Maturitas. 1996 Oct;(2):115–23. [PubMed: 8905602]

von Holst T, Salbach B. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. Maturitas. 2000 Feb 15;34(2):143–53. [PubMed: 10714909]

Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric. 2004 Jun;(2):189–96. [PubMed: 15497908]

Lee BS, Kang BM, Yoon BK, et al. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas. 2007 Aug;20(4):361–9. [PubMed: 17467203]

Lin SQ, Sun LZ, Lin JF, et al. Estradiol 1mg and drospirenone 2mg as hormone replacement therapy in postmenopausal Chinese women. Climacteric. 2011(4):472–81. [PubMed: 21469973]

Lee J, Kim KW, Kim HK, et al. The effect of Rexflavone (Sophorae fructus extract) on menopausal symptoms in postmenopausal women: a randomized double-blind placebo controlled clinical trial. Arch Pharm Res. 2010 Apr;(4):523–30. [PubMed: 20422360]

Dugal R, Hesla K, Sordal T, et al. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand. 2000 Apr;(4):293–7. [PubMed: 10746845]

Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause. 2002 May-Jun;(3):195–207. [PubMed: 11973443]

Donne ML, Caruso C, Mancuso A, et al. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet. 2011 Jun;(6):1319–23. [PubMed: 20577750]

Hunter MS. The Women's Health Questionnaire (WHQ): Frequently Asked Questions (FAQ). Health Qual Life Outcomes. 2003;1(41):41. [PMC free article: PMC212192] [PubMed: 14521718]

Panay N, Ylikorkala O, Archer DF, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007 Apr;(2):120–31. [PubMed: 17453860]

Pornel B, Spielmann D. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period. Gynecol Endocrinol. 2005 Aug;(2):74–81. [PubMed: 16294458]

Pinkerton JV, Kagan R, Portman D, et al. Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause. 2013. PMID: [PubMed: 24149930]

Han KK, Soares JM Jr, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol. 2002 Mar;(3):389–94. [PubMed: 11864664]

White CM, Ip S, McPheeters M, et al. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): 2008. Using Existing Systematic Reviews To Replace De Novo Processes in Conducting Comparative Effectiveness Reviews. [PubMed: 21433402]

Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct;20(15):1684–92. [PMC free article: PMC5142300] [PubMed: 20959578]

Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005 Jan 19;293(3):330–9. [PubMed: 15657326]

Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008 Mar 5;299(9):1036–45. [PubMed: 18319414]

Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003 Oct 1;290(13):1739–48. [PubMed: 14519708]

Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701–12. [PubMed: 15082697]

LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011 Apr;6(13):1305–14. [PMC free article: PMC3656722] [PubMed: 21467283]

Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28;289(20):2651–62. [PubMed: 12771112]

Espeland MA, Brunner RL, Hogan PE, et al. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. J Am Geriatr Soc. 2010 Jul;58(7):1263–71. [PMC free article: PMC2917208] [PubMed: 20649689]

Grady D, Applegate W, Bush T, et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled clinical trials. 1998 Aug;19(4):314–35. [PubMed: 9683309]

Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 3;288(1):58–66. [PubMed: 12090863]

Vickers MR, Martin J, Meade TW, et al. The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health. 2007;7:2. [PMC free article: PMC1828722] [PubMed: 17324282]

Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002 Dec 21-28;360(9350):2001–8. [PubMed: 12504395]

Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology. 2009 Aug;34(7):1065–74. [PubMed: 19297102]

Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004 Sep;104(3):443–51. [PubMed: 15339752]

Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. The Lancet Oncology. 2012 [PMC free article: PMC3412626] [PubMed: 22401913]

Marjoribanks J, Farquhar C, Roberts H, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;7(7):CD004143. [PubMed: 22786488]

Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood pressure. 1992 Aug;1(2):113–9. [PubMed: 1366259]

Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. [PubMed: 23048011]

Simon MS, Chlebowski RT, Wactawski-Wende J, et al. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol. 2012 Nov 10;30(32):3983–90. [PMC free article: PMC3488271] [PubMed: 23008295]

Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update. 2007 Sep-Oct;(5):453–63. [PubMed: 17573406]

Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008 May;15(10):1207–16. [PMC free article: PMC2670848] [PubMed: 18372396]

Beral V. Breast cancer risk in relation to the interval between menopause adn starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296–305. [PMC free article: PMC3039726] [PubMed: 21278356]

Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol. 2008 Jun;15(12):1407–15. [PMC free article: PMC2703736] [PubMed: 18448442]

Hersh. National use of postmenopausal hormone therapy. JAMA. 2004;291(1):47–53. [PubMed: 14709575]

Jemal. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9(3):R28. [PMC free article: PMC1929089] [PubMed: 17477859]

Grodstein F. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol. 1994;83:5–11. [PubMed: 8272307]

Liu B, Beral V, Balkwill A, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008:a386. [PMC free article: PMC2500203] [PubMed: 18617493]

Boland. Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease: a prospective study. Ann Epidemiol. 2002;12(2):131–40. [PubMed: 11880221]

Johnson. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(1):196–203. [PMC free article: PMC2644901] [PubMed: 19124498]

Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998 May 1;128(9):705–12. [PubMed: 9556463]

Rennert G, Rennert HS, Pinchev M, et al. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol. 2009 Sep 20;27(27):4542–7. [PMC free article: PMC2754905] [PubMed: 19704062]

Green J, Czanner G, Reeves G, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer. 2012 May 15;130(10):2387–96. [PubMed: 21671473]

Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007 Apr;4(13):1465–77. [PubMed: 17405972]

Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012 Nov;10(11):2277–86. [PubMed: 22963114]

Karageorgi. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer. 2010;126(1):208–16. [PMC free article: PMC2784268] [PubMed: 19551854]

Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol. 2010 Dec 15;172(12):1394–403. [PubMed: 20961969]

Tsilidis. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2011;22:1075–84. [PubMed: 21637986]

Hildebrand. Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen. Int J Cancer. 2010;127:2928–35. [PubMed: 21351271]

Chien C LC, Heckbert SR, et al. Antidepressant use and breast cancer risk. Breast Cancer Res and Treatment. 2006;95:131–40. [PubMed: 16322894]

Davis S MD. Medication use and the risk of breast cancer. Eur J Epidemiol. 2007;22:319–25. [PubMed: 17487555]

Wernli KJ HJ, Trentham-Dietz A, Newcomb PA. Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf. 2009;18(4):284–90. [PMC free article: PMC2720762] [PubMed: 19226540]

Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005 Mar 16;293(11):1338–47. [PubMed: 15769967]

Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005 Jul 6;294(1):56–65. [PubMed: 15998891]

Lin J, Cook NR, Albert C, et al. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst. 2009 Jan 7;101(1):14–23. [PMC free article: PMC2615459] [PubMed: 19116389]

Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. 2008 May;(5):567–74. [PMC free article: PMC2324136] [PubMed: 18286345]

Maugeri D, Panebianco P, Russo MS, et al. Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years. Archives of gerontology and geriatrics. 1994 Nov-Dec;19(3):253–63. [PubMed: 15374271]

Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcified tissue international. 1997;61 Suppl 1:S23–7. [PubMed: 9263613]

Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA. 2001 Mar;21(11):1482–8. [PubMed: 11255425]

Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med. 2007 Aug 13-27;167(15):1610–8. [PMC free article: PMC2034519] [PubMed: 17698683]

Brasky TM, Lampe JW, Potter JD, et al. Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1696–708. [PMC free article: PMC2906099] [PubMed: 20615886]

Obi N, Chang-Claude J, Berger J, et al. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiol Biomarkers Prev. 2009 Aug;(8):2207–13. [PubMed: 19661079]

Rebbeck TR, Troxel AB, Norman S, et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer. 2007 Apr 1;120(7):1523–8. [PubMed: 17205521]

Archer DF, Pinkerton JV, Guico-Pabia CJ, et al. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause. 2013 Jan;20(1):47–56. [PubMed: 23266840]

Workshop on guidelines to the epidemiology of weak associations. Prev Med. 1987 Mar;16(2):139–212. [PubMed: 3588559]

Lloyd-Jones DM, Martin DO, Larson MG, et al. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med. 1998 Dec 15;129(12):1020–6. [PubMed: 9867756]

Clarkson TB, Utian WH, Barnes S, et al. The role of soy isoflavones in menopausal health: Report of the North American Menopause Society/Wulf H; Utian Translational Science Symposium in Chicago, IL; Menopause; October 2010; pp. 732–53. [PubMed: 21685820]

Horn-Ross PL, John EM, Canchola AJ, et al. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003 Aug;6(15):1158–64. [PubMed: 12902445]

Bandera EV, Williams MG, Sima C, et al. Phytoestrogen consumption and endometrial cancer risk: a population-based case-control study in New Jersey. Cancer Causes Control. 2009 Sep;20(7):1117–27. [PMC free article: PMC2761755] [PubMed: 19353280]

Xu WH, Zheng W, Xiang YB, et al. Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study. BMJ. 2004 May 29;328(7451):1285. [PMC free article: PMC420166] [PubMed: 15136343]

Bolanos R, Francia J. Isoflavones versus hormone therapy for reduction of vertebral fracture risk: indirect comparison. Menopause. 2010 Nov-Dec;(6):1201–5. [PubMed: 20613672]

Moher D, Jadad AR, Nichol G, et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled clinical trials. 1995 Feb;16(1):62–73. [PubMed: 7743790]

Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2) PMID: [PubMed: 26062083]

Sood R, Shuster L, Schroeder D, et al. Abstract: Bioidentical Compounded Hormones - A pharmacokinetic evaluation int he setting of a randomized controlled trial. Menopause. 2010;17(6):1. PMID:

Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008 Jan;(1):77–87. [PubMed: 18165395]

Depomed. Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women. 2012. NCT00755417. PMID:

Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol. 1998 Jan;(1):6–11. [PubMed: 9464712]

Levis S, Strickman-Stein N, Ganjei-Azar P, et al. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: A randomized, double-blind trial. Archives of Internal Medicine. 2011(15):1363–9. [PubMed: 21824950]

Radhakrishnan G, Rashmi, Agarwal N, et al. Evaluation of isoflavone rich soy protein supplementation for postmenopausal therapy. Pakistan Journal of Nutrition. 2009(7):1009–17.

Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. 2006 Dec;19(12):869–79. [PubMed: 17179056]

Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. Am J Obstet Gynecol. 2008 Nov;(5):455–66. [PubMed: 18984078]

Naser B, Schnitker J, Minkin MJ, et al. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause. 2011 Apr;(4):366–75. [PubMed: 21228727]

Aso T, Uchiyama S, Matsumura Y, et al. A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women. J Womens Health (Larchmt). 2012 Jan;21(1):92–100. [PubMed: 21992596]

Hedrick RE, Ackerman RT, Koltun WD, et al. Estradiol gel 0.1% relieves vasomotor symptoms independent of age, ovarian status, or uterine status. Menopause. 2010 Nov-Dec;(6):1167–73. [PubMed: 20720511]

Rigano A, Rigano M, Cancellieri F, et al. Sexually and well-being in early menopause. Effect of transdermal estradiol therapy. Panminerva Med. 2001 Jun;(2):115–8. [PubMed: 11449182]

Simon JA, Stevens RE, Ayres SA, et al. Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome. Climacteric. 2001 Mar;(1):19–27. [PubMed: 11379374]

Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009 Sep;92(3):1025–38. [PubMed: 19635615]

Frei-Kleiner S, Schaffner W, Rahlfs VW, et al. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas. 2005 Aug;16(4):397–404. [PubMed: 16039414]

Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004 Jul-Aug;(4):400–4. [PubMed: 15243277]

Burke GL, Legault C, Anthony M, et al. Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause. 2003 Mar-Apr;(2):147–53. [PubMed: 12627040]

Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006 Apr;63(4):375–82. [PubMed: 16585466]

Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006 Apr;63(4):385–90. [PubMed: 16585467]

Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008 Nov;112(5):970–8. [PubMed: 18978095]

Myers LS. Methodological review and meta-analysis of sexuality and menopause research. Neuroscience and biobehavioral reviews. 1995 Summer;19(2):331–41. [PubMed: 7630587]

Krychman ML. Vaginal estrogens for the treatment of dyspareunia. J Sex Med. 2011 Mar;8(3):666–74. [PubMed: 21091878]

Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006(4):CD001500. [PubMed: 17054136]

National Sleep Foundation. Women and Sleep. 2007.

Carpenter JS, Johnson D, Wagner L, et al. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncology nursing forum. 2002 Apr;29(3):E16–25. [PubMed: 11979290]

Bardia A, Novotny P, Sloan J, et al. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause. 2009 May-Jun;16(3):477–83. [PMC free article: PMC3903404] [PubMed: 19188850]

Sood R, Warndahl RA, Schroeder DR, et al. Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. Maturitas. 2013 Apr;74(4):375–82. [PubMed: 23384975]

NIH. Estrogen Use and Postmenopausal Women; National Institutes of Health Consensus Development Conference Statement; September 13-14, 1979; 1979. [cited 2014 October]; Available from: http://consensus​.nih​.gov/1979/1979EstrogenPostmenopause018html.htm.

Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013 Jan 1;127(1):e6–e245. [PMC free article: PMC5408511] [PubMed: 23239837]

Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 2013 Mar;20(3):342–53. [PubMed: 23435033]

Barrett-Connor E. Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol. 2007 Sep 1;166(5):506–10. [PubMed: 17849510]

Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol. 2007 Sep 1;166(5):511–7. [PubMed: 17646204]

Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014 Aug 19;161(4):249–60. [PubMed: 25069991]

Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005 Jan 4;142(1):37–46. [PubMed: 15537682]

Mahady GB, Low Dog T, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause. 2008 Jul-Aug;15(4 Pt 1):628–38. [PubMed: 18340277]

Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):567–82. [PubMed: 21702069]

Salpeter SR, Buckley NS, Liu H, et al. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med. 2009 Jan;122(1):42–52 e2. [PubMed: 19114171]

Senn S. Statistical issues in drug development. 2nd ed. Chichester, England; Hoboken, NJ: John Wiley & Sons; 2007.